Sphingosine-1-phosphate signaling in the cardiovascular system

被引:102
作者
Peters, Stephan L. M. [1 ]
Alewijnse, Astrid E. [1 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Pharmacol & Pharmacotherapy, NL-1105 AZ Amsterdam, Netherlands
关键词
D O I
10.1016/j.coph.2006.09.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Increasing evidence suggests a key role for the bioactive lipid sphingosine-1-phosphate (S1P) and its G-protein-coupled receptors (S1P(1-5)) in the cardiovascular system. Recent advances in sphingolipid research indicates that cardiomyocyte, vascular smooth muscle and endothelial cell function is greatly influenced by the relative expression and activity both of S1P receptors and of the enzymes involved in sphingolipid metabolism. For instance, the discovery and development of S1P receptor agonists such as FTY720 has clearly indicated the involvement of S1P receptors in the regulation of heart rate. In addition, sphingolipid metabolism induced, for example, by tumour necrosis factor-alpha or angiotensin II plays an important role in vessel structure, function and tone.
引用
收藏
页码:186 / 192
页数:7
相关论文
共 50 条
[1]   Cardiovascular effects of sphingosine-1-phosphate and other sphingomyelin metabolites [J].
Alewijnse, AE ;
Peters, SLM ;
Michel, MC .
BRITISH JOURNAL OF PHARMACOLOGY, 2004, 143 (06) :666-684
[2]   The immune modulator FTY720 targets sphingosine 1-phosphate receptors [J].
Brinkmann, V ;
Davis, MD ;
Heise, CE ;
Albert, R ;
Cottens, S ;
Hof, R ;
Bruns, C ;
Prieschl, E ;
Baumruker, T ;
Hiestand, P ;
Foster, CA ;
Zollinger, M ;
Lynch, KR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (24) :21453-21457
[3]   Pulmonary and vascular pharmacology of sphingosine 1-phosphate [J].
Brinkmann, Volker ;
Baumruker, Thomas .
CURRENT OPINION IN PHARMACOLOGY, 2006, 6 (03) :244-250
[4]  
Bunemann M, 1995, J PHYSIOL-LONDON, V489, P701
[5]   Lysophospholipid receptors as potential drug targets in tissue transplantation and autoimmune diseases [J].
Chun, J ;
Rosen, H .
CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (02) :161-171
[6]   International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature [J].
Chun, J ;
Goetzl, EJ ;
Hla, T ;
Igarashi, Y ;
Lynch, KR ;
Moolenaar, W ;
Pyne, S ;
Tigyi, G .
PHARMACOLOGICAL REVIEWS, 2002, 54 (02) :265-269
[7]   Endothelial nitric oxide synthase activation by tumor necrosis factor α through neutral sphingomyelinase 2, sphingosine kinase 1, and sphingosine 1 phosphate receptors -: A novel pathway relevant to the pathophysiology of endothelium [J].
De Palma, C ;
Meacci, E ;
Perrotta, C ;
Bruni, P ;
Clementi, E .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (01) :99-105
[8]   Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes [J].
Forrest, M ;
Sun, SY ;
Hajdu, R ;
Bergstrom, J ;
Card, D ;
Doherty, G ;
Hale, J ;
Keohane, C ;
Meyers, C ;
Milligan, J ;
Mills, S ;
Nomura, N ;
Rosen, H ;
Rosenbach, M ;
Shei, GJ ;
Singer, II ;
Tian, M ;
West, S ;
White, V ;
Xie, J ;
Proia, RL ;
Mandala, S .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 309 (02) :758-768
[9]   Rac1 modulates sphingosine 1-phosphate-mediated activation of phosphoinositide 3-kinase/Akt signaling pathways in vascular endothelial cells [J].
Gonzalez, E ;
Kou, RQ ;
Michel, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (06) :3210-3216
[10]   Effects of sphingosine 1-phosphate on pacemaker activity in rabbit sino-atrial node cells [J].
Guo, J ;
MacDonell, KL ;
Giles, WR .
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 1999, 438 (05) :642-648